chronic inflammation of the esophagus eosinophilic esophagitis
Conditions
Interventions
Tested product:
ESO-101 is a unique drug delivery system for the upper gastrointestinal tract,
consisting of a capsule holder containing a hard gelatin capsule with a rolled,
thin mucoadhesive film,
Sponsors
EsoCap AG
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Adult patients aged 18-70 years; 2. Confirmed clinicopathological diagnosis of EoE; 3. Active and symptomatic EoE, defined as: a. peak eosinophil count >=15 eosinophils/high-powered field (hpf) at 2 levels of the esophagus at the screening endoscopy (Visit 2) as measured in a total of 6 hpfs derived from 6 biopsies, 2 each from the proximal, mid, and distal segment of the esophagus; b. either a dysphagia or odynophagia severity sore of >=4 on a 11-point numeric rating scale for >=1 day during the 7 days before Screening (Visit 1); 4. Written informed consent; 5. Willingness and ability to comply with the protocol for the duration of the trial; 6. Negative pregnancy test at Screening (Visit 1) and Day 0 (Visit 3) in women of childbearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy); 7. Women of childbearing potential must be willing to use (for a least 3 monthly cycles before the screening endoscopy [Visit 2] and until 4 weeks after the last intake of IMP) a highly effective method of contraception or birth control (failure rate less than 1% per year when used consistently and correctly). Reliable methods for this trial are: a. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal); b. progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); c. intrauterine device or intrauterine hormone-releasing system; d. bilateral tubal occlusion; e. a vasectomized sexual partner; f. sexual abstinence (only accepted as true abstinence when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods, and withdrawal] is not an acceptable method of contraception).
Exclusion criteria
Exclusion criteria: 1. Women who are pregnant, lactating, possibly pregnant or planning a pregnancy during the trial period; 2. Current or past (within the last 3 months) alcohol or drug abuse; 3. Initiation of a diet-modifying food restriction within 4 weeks before the screening endoscopy (Visit 2) until EOT; 4. Use of systemic corticosteroids or biologic immunomodulators within 3 months before the screening endoscopy (Visit 2) until the EOT; 5. History of non-response to treatment of EoE with topical corticosteroid drugs (defined as no improvement of clinical symptoms of EoE after a minimum of 4 weeks corticosteroid therapy used at appropriate doses according to the investigator*s judgment) or requirement of cessation of corticosteroid therapy for EoE treatment due to oral candidiasis or systemic corticosteroid side effects; 6. Use of corticosteroids for treatment of EoE within 4 weeks before the screening endoscopy (Visit 2) until the EOT; 7. Use of inhalable (pulmonary or nasal) corticosteroids within 4 weeks before the screening endoscopy (Visit 2) until the EOT; 8. Asthma requiring corticosteroid therapy in the seasonal allergy period according to the investigator*s judgment based on anamnesis until the EOT; 9. Change in proton pump inhibitor (PPI) dosing regimen within 4 weeks before the screening endoscopy (Visit 2) until the EOT; 10. Use of systemic leukotriene receptor antagonists, immunosuppressant therapy, or chronic oral or systemic anticoagulants (such as coumarin derivates, novel oral and subcutaneous anticoagulants) within 2 weeks before Screening (Visit 1) until the EOT; 11. Unable to swallow a test tablet of about the size of the IMP capsule used in the trial; 12. History of diabetes mellitus; 13. Other severe comorbid condition, concurrent medication, or other issue that renders the patient unsuitable to participate in the trial in the judgment of the investigator, including but not limited to: comorbid condition with an estimated life expectancy of 180mmHg); 14. History of cancer (except non-melanoma skin cancer, or carcinoma in situ of cervix) or treatment with anticancer therapy (chemotherapy, immunotherapy, radiotherapy, hormone therapy for cancer treatment, targeted therapy or gene therapy) within 12 months before Screening (Visit 1) until the EOT; 15. Known intolerability or hypersensitivity to mometasone furoate or any of the IMP excipients (e.g. bovine gelatin, polyvinyl alcohol, polyvinyl acetate, glycerol, sorbitol); 16. Systemic autoimmune disorders or any condition requiring immunosuppression (e.g. methotrexate, cyclosporine, interferon alpha, tumor necrosis factor alpha inhibitors, antibodies to immunoglobulin E) within 3 months before Screening (Visit 1); 17. Mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the trial or presence of any condition that impacts compliance with the trial procedures; 18. Use of any investigational or non-registered product (me
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the efficacy based on the histological response: - absolute change in peak eosinophil count from Baseline to EOT | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the efficacy based on histological response and clinical symptoms: - Proportion of patients with histological remission, defined as the reduction of peak eosinophil count in all esophageal samples to =30%, >=50%, or >=75% from Baseline to EOT - Proportion of patients with histological remission and improvement in the dysphagia severity score from Baseline to EOT To evaluate the efficacy based on clinical response assessed by patient-reported outcome: - Absolute and relative change in dysphagia and odynophagia severity scores from Baseline - Time to achieve symptom relief (defined as 50% improvement in the dysphagia or odynophagia symptoms on an NRS compared to Baseline) To evaluate the efficacy based on endoscopic response - Change in the EREFS1 from Baseline to EOT To evaluate the safety and tolerability - Incidence of treatment-emergent AEs and SAEs - Incidence of AESI - Local tolerability To evaluate patient-reported treatment satisfaction - Patient-reported treatment satisfaction at EOT based on questions about handling, taste, and time necessary for administration To evaluate the efficacy based on histological response - Change in further histological parameters from Baseline to EOT | — |
Countries
Netherlands
Outcome results
None listed